Last reviewed · How we verify

Methadone Treatment-As-Usual

Friends Research Institute, Inc. · Phase 3 active Small molecule

Methadone is a mu-opioid receptor agonist that works by activating opioid receptors in the brain, reducing withdrawal symptoms and cravings in individuals with opioid use disorder.

Methadone is a mu-opioid receptor agonist that works by activating opioid receptors in the brain, reducing withdrawal symptoms and cravings in individuals with opioid use disorder. Used for Treatment of opioid use disorder.

At a glance

Generic nameMethadone Treatment-As-Usual
SponsorFriends Research Institute, Inc.
Drug classopioid agonist
Targetmu-opioid receptor
ModalitySmall molecule
Therapeutic areaAddiction
PhasePhase 3

Mechanism of action

Methadone's mechanism of action involves binding to mu-opioid receptors, which are responsible for the euphoric effects of opioids. By activating these receptors, methadone helps to reduce the severity of withdrawal symptoms and cravings, making it easier for individuals to manage their opioid use disorder. Additionally, methadone's long half-life allows for once-daily dosing, which can improve adherence and reduce the risk of overdose.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: